No Detail Found!

Hearing Loss After the First Low Dose Administration of Cisplatin

Author(s)
Atila Yildirim Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
Evren Fidan Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
Feyyaz Ozdemir Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
Abstract
Cisplatin is commonly used antineoplastic drug that is e ective against di erent types of tumours. Nephrotoxicity, neurotoxicity, and ototoxicity constitute the main dose-limiting side e ects of the drug. We present a case of sensorineural hearing loss after the rst low dose of cisplatin. Five days after receiving an intravenous 30 mg/day at 120 minutes, the patient presented with serious bilateral sensorineural hearing loss. Cisplatin-induced hearing impairment is generally dose-related and cumulative; however, the toxicity can occur after the rst dose without a cumulative high-dose and can be irreversible.
Publication Details
Page(s) 1216-1218
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 9, Year: 2022

Request the full text from PASTIC

Keywords
Hearing loss, Cisplatin, Ototoxicity
0

Citations

0

Downloads

46

Views